about
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trialVitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Transparency and reproducibility in data analysis: the Prostate Cancer Prevention TrialA functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial.Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial.Moving a randomized clinical trial into an observational cohortOpportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer riskDental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702.Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).Finasteride decreases the risk of prostatic intraepithelial neoplasia.Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention.Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.
P50
Q24633239-742AEEB1-FA64-4B50-93F3-0B78A77FAC55Q29620308-805A2C30-6AED-4D0D-A599-9861070831E8Q33532998-DFBE13CF-5457-4BF4-A84D-48478BC27F12Q34135313-1DAD7C25-6C78-4A91-AD09-25E7F49B9010Q35388641-E6ED55AC-14A9-4FC4-AB0F-FC42B1E9EC62Q36781932-A4EE3B1E-F2B4-4BAE-8114-F2C7B9843C6DQ36797175-DEBBF5C7-CFDF-4DE6-9487-DA13AC7C35B1Q37171404-17CEDDDF-CBA0-419A-90B3-988D3EB9F1FAQ37379368-FB86FA91-900B-4BAB-B5C8-2FECEAE9F88CQ37683660-C1D2C9C2-F237-437D-8763-4C415D6A1D16Q38383744-3892F0DF-74CC-46F0-8930-82D63B8438ABQ39187895-A3540952-F8C7-4144-97AB-C8DC27C867E4Q39797093-E99FA789-14C4-4286-B972-07CFBAFC5C39Q46200270-F1612BC7-BB74-4DEB-AA28-101737413670Q47137343-68DC4C6D-5746-4EE9-84A1-801DC949B5AEQ51902123-DA1A4938-36B7-4F34-833D-03A390C15E3C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Amy K Darke
@ast
Amy K Darke
@en
Amy K Darke
@es
Amy K Darke
@nl
Amy K Darke
@sl
type
label
Amy K Darke
@ast
Amy K Darke
@en
Amy K Darke
@es
Amy K Darke
@nl
Amy K Darke
@sl
prefLabel
Amy K Darke
@ast
Amy K Darke
@en
Amy K Darke
@es
Amy K Darke
@nl
Amy K Darke
@sl
P106
P21
P31
P496
0000-0002-9821-2065